Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Eastern Cooperative Oncology Group
National Institutes of Health Clinical Center (CC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Eli Lilly and Company
University of Southern California
Institut Claudius Regaud
City of Hope Medical Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Eli Lilly and Company
University of Arizona
Sanofi
Sanofi
Exelixis
Peking Union Medical College Hospital
Jonsson Comprehensive Cancer Center
University of Pennsylvania
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
University Medical Center Groningen
British Columbia Cancer Agency
Hoffmann-La Roche
Instituto do Cancer do Estado de São Paulo
Sanofi
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
University Hospital, Basel, Switzerland
Eli Lilly and Company
Aristotle University Of Thessaloniki
Sanofi
Mayo Clinic
Universidad Nacional Autonoma de Mexico
First Affiliated Hospital of Fujian Medical University
NantCell, Inc.
Turning Point Therapeutics, Inc.
M.D. Anderson Cancer Center
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
National Cancer Institute (NCI)
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
TYK Medicines, Inc
Hoffmann-La Roche
National Cancer Institute (NCI)
University College, London
Boston Pharmaceuticals
Power Life Sciences Inc.
Austral University, Argentina
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Novo Nordisk A/S